BA
CORT icon

Bellwether Advisors’s Corcept Therapeutics CORT Stock Holding History

Bellwether Advisors’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-208
Closed -$4K – 555
2021
Q2 		$4K Sell
208
-122
-37% -$2.71K ﹤0.01% 332
2021
Q1 		$7K Buy
+330
New +$8.81K ﹤0.01% 274

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

Bellwether Advisors's CORT Position: Q3 2021 in Review

Bellwether Advisors sold out of Corcept Therapeutics (CORT) in Q3 2021, closing a stake of 208 shares — an estimated $4K sold.

Bellwether Advisors first reported a position in CORT in Q1 2021 and held it in 2 quarters. The position peaked at $7K in Q1 2021. 201 funds tracked by Wall St. Rank hold CORT as of Q3 2021.

  • Bellwether Advisors reported no remaining Corcept Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Bellwether Advisors sold 208 Corcept Therapeutics shares in Q3 2021, an estimated $4K.
  • Bellwether Advisors first reported a position in Corcept Therapeutics in Q1 2021 and held it in 2 quarters.
  • Bellwether Advisors's Corcept Therapeutics position peaked at $7K in Q1 2021.
  • 201 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q3 2021.

Based on Bellwether Advisors's 13F filing for Q3 2021, filed 12 Nov 2021.